详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

Antiviral Abidol is Associated with the Reduction of In-Hospital Mortality in COVID-19 Patients.

文献详情

资源类型：

Pubmed体系：

收录情况： ◇ 卓越：高起点新刊 ◇ 中华系列

作者：

单位： [1]Department of Cardiology, Tongji Hospital, Tongji Medical College, HuazhongUniverisity of Science & Technology, Wuhan 430030, China [2]Department ofCardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006,China [3]Department of Cardiology, Wuhan First Hospital, Wuhan 430022, China [4]Department of Cardiology, Tianyou Hospital Affiliated to Wuhan University ofScience & Technology, Wuhan 430064, China [5]Mailman School of PublicHealth, Columbia University, NewYork, New York 10027, USA [6]College ofPharmacy, Nanjing Medical University, Nanjing 210002, China.

出处：

DOI：

ISSN：

关键词： Abidol Coronavirus induced disease Inflammation In-hospital death

摘要：

Coronavirus disease 2019 (COVID-19) is a global public health crisis. There are no specific antiviral agents for the treatment of SARS-CoV-2. Information regarding the effect of Abidol on in-hospital mortality is scarce. The present study aimed to evaluate the treatment effect of Abidol for patients with COVID-19 before and after propensity score matching (PSM).This retrospective cohort study analyzed 1019 patients with confirmed COVID-19 in China from December 22, 2019 to March 13, 2020. Patients were divided to Abidol (200 mg, tid, 5-7 days, n = 788, 77.3%) and No-Abidol (n = 231, 22.7%) groups. The primary outcome was the mortality during hospitalization.Among 1019 COVID-19 patients, the age was (60.4 ± 14.5) years. Abidol-treated patients, compared with No-Abidol-treated patients, had a shorter duration from onset of symptoms to admission, less frequent renal dysfunction, lower white blood cell counts (lymphocytes <0.8) and erythrocyte sending rate, lower interleukin-6, higher platelet counts and plasma IgG and oxygen saturation, and less frequent myocardial injury. The mortality during hospitalization before PSM was 17.9% in Abidol group and 34.6% in No-Abidol (hazard ratio (HR) = 2.610, 95% confident interval (CI): 1.980-3.440), all seen in severe and critical patients. After PSM, the in-hospital death was 13.6% in Abidol and 28.6% in No-Abidol group (HR = 2.728, 95% CI: 1.598-4.659).Abidol-treatment results in less in-hospital death for severe and critical patients with COVID-19. Further randomized study is warranted to confirm the findings from this study.Copyright © 2021 The Chinese Medical Association, published by Wolters Kluwer Health, Inc.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2020]版：

无

最新[2025]版：

大类 | 4 区医学

小类 | 4 区心脏和心血管系统

第一作者：

第一作者单位： [1]Department of Cardiology, Tongji Hospital, Tongji Medical College, HuazhongUniverisity of Science & Technology, Wuhan 430030, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Cardiology, Tongji Hospital, Tongji Medical College, HuazhongUniverisity of Science & Technology, Wuhan 430030, China [2]Department ofCardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006,China [6]College ofPharmacy, Nanjing Medical University, Nanjing 210002, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Risk factors for in-hospital death in 2,179 patients with acute aortic dissection [2]Laboratory abnormalities and risk factors associated with in-hospital death in patients with severe COVID-19 [3]Kidney disease is associated with in -hospital death of patients with COVID-19 [4]Kidney disease is associated with in-hospital death of patients with COVID-19 [5]Tocilizumab: The Key to Stop Coronavirus Disease 2019 (COVID-19)-Induced Cytokine Release Syndrome (CRS)? [6]Coronavirus disease 2019 death prediction by electrocardiographic abnormalities and elevated D-dimer levels [7]Early identification of patients with severe COVID-19 at increased risk of in-hospital death: a multicenter case-control study in Wuhan [8]How to predict the death risk after an in-hospital cardiac arrest (IHCA) in intensive care unit? A retrospective double-centre cohort study from a tertiary hospital in China [9]Recent Advances in Nanomaterials for the Treatment of Acute Kidney Injury [10]主动脉夹层院内死亡危险因素十年回顾性分析